Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles. [PDF]
Mannes M, Zelek WM, Trouw LA.
europepmc +1 more source
C3 glomerulopathy in transplant "like yet unlike native": Pathophysiology, recent advances in therapeutics and evolving paradigms. [PDF]
Chutani A, Norouzi S, Lerma EV.
europepmc +1 more source
Excessive C5 conversion prevents C9 polymerisation and subsequent MAC-dependent killing of Klebsiella pneumoniae. [PDF]
Dawoodbhoy KM +7 more
europepmc +1 more source
Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring. [PDF]
Saccà F, Pelto R.
europepmc +1 more source
Recombinant Ornithodoros moubata Saliva-derived Small Protein Complement C5 Inhibitor [PDF]
openaire +1 more source
Correction: Sez6L2 inhibits complement by facilitating factor I cleavage of C3b and accelerating the decay of C3 convertases. [PDF]
Qiu WQ +7 more
europepmc +1 more source
Beyond Vaccination: Persistent Meningococcal Risk in Anti-C5-Treated aHUS-Case Report and Review of Literature. [PDF]
Matarese S +11 more
europepmc +1 more source
PNH extravascular hemolysis: exploring clinical significance. [PDF]
Notaro R, Risitano AM.
europepmc +1 more source
Modulator-induced conformational changes in complement C5, implications for function and drug design. [PDF]
Zhivnov A +7 more
europepmc +1 more source
Complement and transplant-associated thrombotic microangiopathy: Current and future approaches. [PDF]
Cugno M, Onida F, Lämmle B.
europepmc +1 more source

